A Pilot Study of Safety and Feasibility of Stem Cell Therapy for Aids Lymphoma Using Stem Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs

Trial Profile

A Pilot Study of Safety and Feasibility of Stem Cell Therapy for Aids Lymphoma Using Stem Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs HIV T-cell therapy (Primary) ; Carmustine; Cyclophosphamide; Etoposide; Filgrastim
  • Indications Lymphoma
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 17 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
    • 17 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
    • 17 Feb 2017 Planned End Date changed from 1 Dec 2015 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top